文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

撒哈拉以南非洲多国HIV耐药模式与高病毒载量关联分析

Nationwide patterns of HIV drug resistance and high viral load in Sub-Saharan African countries.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该研究基于2015–2019年13个非洲国家PHIA调查的2292例≥15岁参与者数据,分析HIV耐药突变模式及其与高病毒载量的关联。结果显示NNRTI和NRTI耐药最为普遍(分别43%–60%和37%–53%),多种耐药突变与高病毒载量强相关。

要点

  • NNRTI和NRTI耐药在多数国家普遍,PI耐药较低(0.2%–5%)。
  • K103N、Y181C、M184V、K65R等突变与高病毒载量强相关。
  • 加强耐药监测、优化ART方案和改善依从性对控制耐药至关重要。

核心结论

  • NNRTI和NRTI耐药在撒哈拉以南非洲多国普遍存在,多种耐药突变与高HIV病毒载量强相关。

研究设计与样本

  • 对2015–2019年13个非洲国家PHIA调查的回顾性数据进行二次分析,纳入2292例≥15岁且有HIV耐药基因型数据的参与者。

主要发现

  • 2292例参与者中1949例(85%)高病毒载量,超过三分之一未接受ART。
  • 多数国家NNRTI耐药率43%–60%,NRTI耐药率37%–53%,PI耐药率0.2%–5%。
  • NNRTI中16/39个突变(如K103N、Y181C)和NRTI中18/34个突变(如M184V、K65R)在≥10个国家与高病毒载量强相关。
  • PI中Q58E和L33F在多国与高病毒载量强相关。

关键数值与推荐

  • 高病毒载量定义为HIV RNA≥1000 copies/mL。
  • 耐药突变按药物类别分为NNRTI、NRTI和PI。

临床怎么用

  • 应加强HIV耐药监测,优化ART方案并改善依从性以遏制耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To (1) assess the prevalence and patterns of HIV drug resistance (HIVDR) mutations, (2) identify correlations between different HIVDR mutations within drug classes, and (3) examine the association between resistance mutations and high HIV viral load. METHODS: We conducted a secondary analysis of retrospective data collected through the Population-based HIV Impact Assessment (PHIA) surveys conducted between 2015 and 2019 in 13 African countries. We included participants aged ≥15 years with available HIVDR genotyping. The primary outcomes were (1) prevalence of HIVDR mutations, categorized by drug class into non-nucleoside reverse transcriptase inhibitors (NNRTIs), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), and Protease inhibitors (PIs); (2) high HIV viral load (VL), (HIV RNA ≥1000 copies/mL). RESULTS: The analysis included 2292 participants, with a median age range between 31 and 41 years. More than one-third of participants were not receiving ART. Of all participants, 1949 (85%) had high VL. Resistance to NNRTIs and NRTIs was the most prevalent in most countries, ranging from 43% to 60%, and 37% to 53%, respectively. Resistance to PI ranges from 0.2% to 5%. Multiple drug resistance mutations across all ART classes were strongly associated with high VL. Among NNRTIs, 16/39 mutations (e.g. K103N, Y181C) and 18/34 NRTI mutations (e.g. M184V, K65R) showed strong associations with high VL in ≥10 countries. For PIs, Q58E and L33F emerged as key mutations strongly associated with high VL across multiple nations. CONCLUSIONS: Strengthening resistance surveillance, optimising ART regimens, and improving adherence are crucial to curb resistance and sustain HIV epidemic control.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Elbur AI, Gandla S, Nakka R, et al. Nationwide patterns of HIV drug resistance and high viral load in Sub-Saharan African countries. J Antimicrob Chemother. 2026. PMID: 41692676. doi:10.1093/jac/dkaf497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。